Cargando…
Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus
BACKGROUND: Vaccinia viruses have been used as a model for viral disease and as a protective live vaccine. METHODOLOGY AND PRINCIPAL FINDINGS: We investigated the immunogenicity of an attenuated strain of vaccinia virus engineered to inactivate the N1L gene (vGK5). Using the intranasal route, this r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553181/ https://www.ncbi.nlm.nih.gov/pubmed/18830408 http://dx.doi.org/10.1371/journal.pone.0003323 |
_version_ | 1782159485039542272 |
---|---|
author | Mathew, Anuja O'Bryan, Joel Marshall, William Kotwal, Girish J. Terajima, Masanori Green, Sharone Rothman, Alan L. Ennis, Francis A. |
author_facet | Mathew, Anuja O'Bryan, Joel Marshall, William Kotwal, Girish J. Terajima, Masanori Green, Sharone Rothman, Alan L. Ennis, Francis A. |
author_sort | Mathew, Anuja |
collection | PubMed |
description | BACKGROUND: Vaccinia viruses have been used as a model for viral disease and as a protective live vaccine. METHODOLOGY AND PRINCIPAL FINDINGS: We investigated the immunogenicity of an attenuated strain of vaccinia virus engineered to inactivate the N1L gene (vGK5). Using the intranasal route, this recombinant virus was 2 logs less virulent compared to the wildtype VACV-WR. Infection by the intranasal, intraperitoneal, and tail scarification routes resulted in the robust induction of cytolytic virus-specific CD8 T cells in the spleens and the lungs. VACV-specific antibodies were also detected in the sera of mice infected 3–5 months prior with the attenuated vGK5 virus. Finally, mice immunized with vGK5 were significantly protected when challenged with a lethal dose of VACV-WR. CONCLUSIONS: These results indicate that the attenuated vGK5 virus protects against subsequent infection and suggest that the N1L protein limits the strength of the early antiviral CD8 T cell response following respiratory infection. |
format | Text |
id | pubmed-2553181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-25531812008-10-02 Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus Mathew, Anuja O'Bryan, Joel Marshall, William Kotwal, Girish J. Terajima, Masanori Green, Sharone Rothman, Alan L. Ennis, Francis A. PLoS One Research Article BACKGROUND: Vaccinia viruses have been used as a model for viral disease and as a protective live vaccine. METHODOLOGY AND PRINCIPAL FINDINGS: We investigated the immunogenicity of an attenuated strain of vaccinia virus engineered to inactivate the N1L gene (vGK5). Using the intranasal route, this recombinant virus was 2 logs less virulent compared to the wildtype VACV-WR. Infection by the intranasal, intraperitoneal, and tail scarification routes resulted in the robust induction of cytolytic virus-specific CD8 T cells in the spleens and the lungs. VACV-specific antibodies were also detected in the sera of mice infected 3–5 months prior with the attenuated vGK5 virus. Finally, mice immunized with vGK5 were significantly protected when challenged with a lethal dose of VACV-WR. CONCLUSIONS: These results indicate that the attenuated vGK5 virus protects against subsequent infection and suggest that the N1L protein limits the strength of the early antiviral CD8 T cell response following respiratory infection. Public Library of Science 2008-10-02 /pmc/articles/PMC2553181/ /pubmed/18830408 http://dx.doi.org/10.1371/journal.pone.0003323 Text en Mathew et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Mathew, Anuja O'Bryan, Joel Marshall, William Kotwal, Girish J. Terajima, Masanori Green, Sharone Rothman, Alan L. Ennis, Francis A. Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title | Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title_full | Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title_fullStr | Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title_full_unstemmed | Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title_short | Robust Intrapulmonary CD8 T Cell Responses and Protection with an Attenuated N1L Deleted Vaccinia Virus |
title_sort | robust intrapulmonary cd8 t cell responses and protection with an attenuated n1l deleted vaccinia virus |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553181/ https://www.ncbi.nlm.nih.gov/pubmed/18830408 http://dx.doi.org/10.1371/journal.pone.0003323 |
work_keys_str_mv | AT mathewanuja robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT obryanjoel robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT marshallwilliam robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT kotwalgirishj robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT terajimamasanori robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT greensharone robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT rothmanalanl robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus AT ennisfrancisa robustintrapulmonarycd8tcellresponsesandprotectionwithanattenuatedn1ldeletedvacciniavirus |